Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
57%(4 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
6
75%
Ph phase_1
2
25%

Phase Distribution

2

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
6(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
87.5%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (25.0%)
Phase 26 (75.0%)

Trials by Status

completed788%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT02534909
completedphase_2

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

NCT01526889
completedphase_2

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

NCT01527500
completedphase_2

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

NCT01535950
terminatedphase_2

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

NCT01624636
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02534909Phase 2

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed
NCT01526889Phase 2

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

Completed
NCT01527500Phase 2

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

Completed
NCT01535950Phase 2

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Completed
NCT01624636Phase 2

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Terminated
NCT02878616Phase 1

Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316

Completed
NCT02515942Phase 2

CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)

Completed
NCT01255462Phase 1

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8